Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch Health Companies Inc.

https://www.bauschhealth.com/

Latest From Bausch Health Companies Inc.

Bausch + Lomb Patiently 'Semi-Private' While Bausch Health Plots Path To Spin-Out Completion

B+L using period of Bausch Health’s near-full ownership to plan for future. "When the spin comes, then we can spend a lot more time with our investors. But right now, I just have to take the elevator down two floors and I can see the 90% shareholder,” says CEO Brent Saunders.

OTC Drugs M & A

Terns Hits In NASH, But Trails Its Rivals

TERN-501 monotherapy looks serviceable in a mid-stage NASH trial, but others are ahead. Perhaps partnership is the way forward.

Clinical Trials Companies

Finance Watch: Apogee, Sagimet Launch First Big US IPOs Of The Summer

Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.

Financing Growth

Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.

Drug Approval Standards Complete Response Letters
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • AB Sanitas
    • Afexa Life Sciences Inc.
    • Amoun Pharmaceutical
    • Aton Pharma, Inc.
    • Bausch Health Ireland Limited
    • Bausch + Lomb Holding International
    • Biovail Corporation
    • Callisto Pharmaceuticals, Inc. Dendreon Corporation
    • Dermik Laboratories, Inc.
    • Dow Pharmaceutical Sciences, Inc.
    • Eyetech Inc.
    • Graceway Pharmaceuticals, LLC
    • ICN Pharmaceuticals, Inc.
    • iNova Diagnostics, Inc.
    • Instituto Terapeutico Delta Ltda
    • Medicis Aesthetics Holdings Inc
    • Medicis Pharmaceutical Corporation
    • Mercury (Cayman) Holdings
    • OraPharma, Inc.
    • Ortho Dermatologics
    • Prestwick Pharmaceuticals, Inc.
    • PharmaSwiss S.A.
    • Pedinol Pharmacal, Inc.
    • Salix Pharmaceuticals Ltd. (InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.)
    • Sanitas AB
    • Solta Medical, Inc.
    • SPI Pharmaceuticals Inc
    • Synergetics USA, Inc.
    • Synergy Pharmaceuticals Inc.(SGYP)
    • Technolas Perfect Vision GmbH (TPV)
    • Ucyclyd Pharma, Inc.
    • Unilens Vision, Inc.
    • Viratek Pharma Inc
    • Valeant Pharmaceuticals International, Inc.
    • Xcel Pharmaceuticals, Inc.
UsernamePublicRestriction

Register